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Although minimal residual disease (MRD) following allo-SCT is associated with a relapse probability exceeding 90%, 2 efficacy of imatinib in the setting of MRD has been shown. However, the prognosis of patients on imatinib treatment with continued detection of Bcr-Abl transcripts is extremely poor. 3 Here, we present a case of Ph þ ALL with continued detection of Bcr-Abl transcripts following allo-SCT, in which the patient was successfully treated with imatinib and low-dose interferon (IFN)-a-2b.
A 50-year-old Japanese man was admitted to our hospital complaining of general fatigue. His hemoglobin level was 15.3 g per 100 ml, white blood cell count was 44.5 Â 10 9 /l (83% blast cells) and platelet count was 217 Â 10 9 /l. Blast cells were negative for myeloperoxidase and positive for CD10, CD19, CD34 and TdT (terminal deoxynucleotidyl transferase). Cytogenetic study revealed a Philadelphia chromosome. A real-time PCR showed amplification of the P-190
Bcr-Abl transcript (Bcr-Abl/ GAPDH ratio ¼ 1.6 Â 10
À2
). With these data, the patient was diagnosed with Ph þ ALL and chemotherapy was started ( Figure 1 ). The patient received three induction-consolidation courses alternating hyper-CVAD (cyclophosphamide, vincristine, adriamycin and dexamethasone) with high-dose methotrexate and cytarabine, concurrently with imatinib. 4 Although he achieved a morphological complete remission (CR) after induction chemotherapy, Bcr-Abl transcripts were persistently detected by real-time PCR assay (6.0 Â 10 À4 ) even after two courses of consolidation chemotherapy. A peripheral blood stem cell transplant from a human leukocyte antigen-matched, related female donor was performed. His conditioning regimen consisted of cyclophosphamide and total body irradiation. Cyclosporine A (CsA) and short-term methotrexate were used for prophylaxis against graft-versus-host disease (GVHD).
Neutrophil engraftment was achieved on day þ 14. Examination of his bone marrow revealed morphological CR, but Bcr-Abl transcripts were detected by real-time PCR assay (5.4 Â 10
À5
). This technique can detect a single Bcr-Abl-positive leukemic blast cell among more than 10 5 background cells. Because failure to achieve PCR negativity soon after allo-SCT was predictive of ongoing clinical relapse, we chose to pursue careful molecular monitoring every 2 weeks. CsA withdrawal was initiated and imatinib was started at a daily dose of 400 mg on day þ 20. Grade I GVHD of the skin developed, but resolved spontaneously. On day þ 44, real-time PCR assay showed persistence of Bcr-Abl transcripts (1.3 Â 10
). Although CsA was discontinued and the dose of imatinib was escalated to a daily dose of 600 mg on day þ 51, the Bcr-Abl transcript level increased on day þ 58 (3.4 Â 10
). IFN-a-2b was started at 3 MU once a week, subcutaneously, on day þ 64. The second and third doses of IFN-a-2b were administered on days þ 71 and þ 78, respectively. On day þ 77, a skin GVHD and lichenoid lesion of the oral cavity had emerged, and oral GVHD was confirmed by lip biopsy. After three doses of IFN-a-2b, by day þ 97, Bcr-Abl transcripts were undetectable. Because he was deemed to have progressive GVHD, IFN-a-2b was discontinued after the initial three doses. For controlling GVHD, low-dose prednisolone was started on day þ 101, resulting in a gradual resolution of GVHD.
On day þ 216, using highly sensitive conventional reverse transcriptase-PCR, we found Bcr-Abl transcripts in two out of six assays. Imatinib was continued at a daily dose of 600 mg, and real-time PCR assay remained negative from day þ 97 (33 days after the start of the combination treatment) through day þ 464.
One prospective multicenter phase II study explored the ability of imatinib in decreasing the incidence of relapse among Ph þ ALL patients with MRD following allo-SCT. In that study, imatinib could render Bcr-Abl transcripts undetectable in about half of the 27 patients enrolled, but most patients in whom MRD persisted after a 6 to 10-week imatinib trial period relapsed, and dose escalation did not impact the PCR response. 3 In our case, the persistent detection of Bcr-Abl transcripts after 6 weeks of imatinib treatment was likely to be predictive of hematological relapse. Because escalation of imatinib did not seem capable of achieving a negative PCR result, we chose to add IFN-a-2b to imatinib.
This case builds on some evidence suggesting that lowdose IFN-a-2b in conjunction with imatinib is a promising treatment for adult patients with Ph þ ALL who have persistent MRD following allo-SCT. 5, 6 In a small series of six patients with Ph þ ALL who were ineligible for SCT and were treated with imatinib and IFN-a, two out of the five MRD þ patients were alive in hematologic and molecular remission after 11 and 15 months, respectively. 5 Additionally, at the cellular level, the synergistic effects of imatinib and IFN-a have been demonstrated in vitro in Ph þ leukemia. 6 In our patient, a rapid response to IFN-a-2b and a sustained molecular CR on day þ 464 suggested the possibility that the GVL (graft-versus-leukemia) effect was enhanced by IFN-a-2b. Indeed, this may have played a central role in the antileukemic response. This in fact occurred in one case series in which the administration of IFN-a with or without granulocyte macrophage colony stimulating factor produced CR in five out of seven acute leukemia patients who had relapsed following allo-SCT. 7 The immunological modification of IFN-a following allo-SCT is not fully understood, but hypotheses include the activation of recipient-or donor-derived dendritic cells that indirectly present alloantigen and activate donor T cells. 7, 8 In contrast to chronic myelogenous leukemia (CML), the ability of donor lymphocyte infusion to induce durable remission has not yet been demonstrated in relapsed acute leukemia. 9 The increasing tumor immunogenecity caused by IFN-a, via dendritic cell activation, may be more important for the GVL effect in acute leukemia. Accordingly, we chose to use IFN-a-2b rather than donor lymphocyte infusion. There have been some reports of using IFN-a in cases of cytogenetic or hematologic CML relapse after allo-SCT. Induction of GVHD and GVL by IFN-a alone is rare under these circumstances. 10 In cases where tumor burden is small and almost all hematopoietic systems are occupied with donor-derived cells, IFN-a may exert immunological and antileukemic effects more efficiently.
Used in conjunction with imatinib, IFN-a-2b, even at very low doses, may be a promising option for Ph þ ALL patients with persistent MRD being treated with singleagent imatinib following allo-SCT. Careful molecular monitoring may be very important, however, for both initiation of imatinib and subsequent treatment decisions (for example, IFN-a-2b). Letter to the Editor
